Evommune: T. Rowe Price reports 2.3% shareholding
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Evommune, Inc. (EVMN) is the issuer in an amended Schedule 13G in which T. Rowe Price Associates, Inc. reported 851,866 common shares, or 2.3% of the class, as beneficially owned. The firm reported sole voting and dispositive power over 851,866 shares and no shared voting or dispositive power. It stated that the report is not an admission of beneficial ownership and expressly denied being the beneficial owner of the securities.
Key Figures
Key Terms
beneficially owned regulatory
Sole Voting Power regulatory
Sole Dispositive Power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.